PARP1 and breast carcinoma: We concluded that the simultaneous inhibition of PARP and Akt using olaparib and capivasertib triggers metabolic collapse and apoptotic cell death in breast cancer cells, particularly in triple-negative breast cancer (TNBC) and MCF7 cells.